Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Here are Investing.com’s stocks of the week. Microsoft was one of many tech giants that reported earnings this week, with the company topping profit and revenue expectations. MSFT shares jumped more ...

CNBC's Jim Cramer on Friday highlighted the most market-moving events of next week, including earnings reports from Disney, Palantir and Uber. He also remarked on the turbulent nature of the market as ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...

A decision is expected in the fourth quarter of 2025.

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.